Related Experiment Video
Updated: Jul 13, 2026
08:46
Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives
Published on: September 16, 2021
WITHDRAWN: Bromocriptine for unexplained subfertility in women
E Hughes1, J Collins, P Vandekerckhove
1McMaster University, Rm HSC-4F7, Dept of Obstetrics & Gynecol, 1200 Main St West, Hamilton, Ontario, Canada, L8N 3Z5. hughese@mcmaster.ca
The Cochrane Database of Systematic Reviews
|July 20, 2007
Summary
Bromocriptine does not improve conception rates for unexplained subfertility in women. More research is needed, especially for those with galactorrhea.
Area of Science:
- Reproductive Endocrinology
- Infertility Research
Background:
- Bromocriptine is known to treat hyperprolactinemic amenorrhea.
- Its potential efficacy in unexplained subfertility warrants investigation.
Purpose of the Study:
- To evaluate the effectiveness of bromocriptine in treating unexplained subfertility in women.
Main Methods:
- Systematic review of randomized controlled trials from the Cochrane Subfertility Review Group register.
- Inclusion criteria: bromocriptine versus placebo or no treatment in women with unexplained subfertility.
- Data extraction and quality assessment performed independently by two reviewers.
Main Results:
- Three double-blind, placebo-controlled trials with a total of 127 women were included.
- Bromocriptine treatment did not significantly improve conception rates compared to placebo (OR 1.12, 95% CI 0.48-2.57).
Conclusions:
- Current evidence is insufficient to support bromocriptine use for unexplained subfertility.
- Further trials may be beneficial for women with unexplained subfertility and co-existing galactorrhea.
Related Concept Videos
01:28Infertility in Females
Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of endometrial...
Endometriosis, a condition characterized by abnormal growth of endometrial...
01:23Infertility in Males
Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...
01:30Hormonal Control of the Ovarian Cycle
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
01:22Hormonal Regulation of the Menstrual Cycle
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.